DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia.

Author(s): Grootens KP, van Veelen NM, Sitskoorn MM, Sabbe BG, Peuskens J, Buitelaar JK, Verkes RJ, Kahn RS.

Affiliation(s): CWZ General Hospital Nijmegen, Dept. of Psychiatry, Postbus 9015, 6500 GS Nijmegen, The Netherlands. k.grootens@cwz.nl

Publication date & source: 2010, Eur Neuropsychopharmacol. , 20(12):907-12

INTRODUCTION: To enhance functional outcome in schizophrenia improvement of cognitive symptoms is crucial. EXPERIMENTAL PROCEDURES: Using a comprehensive test battery, this follow-up examines cognitive effects in patients with recent-onset schizophrenia after a change of medication following insufficient clinical response and intolerance. RESULTS: After eight weeks cognitive outcomes had not improved in the patients having switched from olanzapine to ziprasidone (n=11; mean dose 136 mg) nor in those having switched from ziprasidone to olanzapine (n=10; mean 16 mg), while the symptoms of patients maintaining olanzapine (n=18; mean 10.9 mg) or ziprasidone (n=18; mean 88.9 mg) treatment had not improved further. DISCUSSION: The findings suggest that also in early-stage schizophrenia the antipsychotics tested affect cognitive symptoms similarly.

Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017